Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 7Neoplasms 3Liver Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Piebaldism 1Patient Compliance 1Pathologic Complete Response 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Stable Metastatic Colorectal Cancer 1Meningioma 1Melanoma 1MCRC 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Metastases 1Leiomyosarcoma 1

Interventions

Bevacizumab 4Paclitaxel 2Lutetium-177 2Lutetium 2ribociclib 1repotrectinib 1regorafenib 1pembrolizumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1camrelizumab 1atezolizumab 1apatinib 1Tretinoin 1Radiation 1Propranolol 1Leucovorin 1Irinotecan 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Clinical Trials, Phase II as Topic 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Neoplasms × regorafenib × Clear all
NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡